drugset / Trial / NCT00827684

Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

NCT00827684

Phase 2 Completed 50 enrolled Vejle Hospital
Treatment

Summary

The purpose of this study is to investigate the safety and efficacy of temsirolimus as a single drug, and of temsirolimus in combination with irinotecan in chemotherapy resistant patients with KRAS mutated colorectal cancer.

Timeline

Start
2009-03
Primary completion
2011-01
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule
Subject Temsirolimus Small molecule

Indications